Abstract 32P
Background
International guidelines recommend a combination of NK1, 5-HT3 receptor antagonists, and dexamethasone (DEX) as standard antiemetic therapy for patients treated with a doxorubicin and cyclophosphamide (AC) regimen. However, DEX has been associated with several side effects, including diabetes, osteoporosis, and immunosuppression. Additionally, pneumocystis pneumonia, a rare but fatal condition, has been reported, predominantly in patients undergoing the dose-dense AC (ddAC) regimen.
Methods
We recruited 30 patients with Stage I-III breast cancer who received the ddAC regimen. Patients were administered prophylactic olanzapine (OLZ) 5 mg/day on days 1 to 4 in addition to the standard three-drug combination antiemetic regimen, with DEX omitted on days 2 and 3. Nausea/vomiting and drowsiness were evaluated using a 4-point Likert scale questionnaire previously employed in the J-FORCE study, which assessed the efficacy of OLZ 5 mg in high-emetic-risk regimens. The primary endpoint was complete response (CR) rate in the delayed phase (24-120 hours post chemotherapy administration) of the first cycle. Secondary endpoints included the total control (TC) rate of nausea and vomiting, complete control (CC) rate, degree of daytime sleepiness, and quality of life as assessed by EORTC QLQ-C30 Ver.3.
Results
Among the participants, 22 patients (73%) received ddAC as neoadjuvant chemotherapy and 8 (27%) as adjuvant chemotherapy. Median age at the start of treatment was 56 years. CR rates were 73% and 63% in the acute and delayed periods, respectively. TC and CC rates in the acute period were 60% and 73%, whereas those in the delayed period were 36.6% and 63%, respectively. In both periods, 40% of patients experienced moderate or severe sleepiness. Mean scale scores for nausea on the EORTC QLQ-C30 remained within the Minimally Important Difference score level throughout the 4th cycles of treatment.
Conclusions
This prospective pilot study suggests that the addition of OLZ 5mg allows the omission of steroids without a worsening of CINV in patients with ddAC.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
50P - A nationwide retrospective cohort study of the response to neoadjuvant chemotherapy between HER-2 low and HER-2 negative non-metastatic breast cancer in Qatar: A real-world analysis
Presenter: Ahmed Kardousha
Session: Poster Display
Resources:
Abstract
51P - Four-year outcomes of hypofractionated postmastectomy radiation therapy of 39 Gy in 13 fractionations
Presenter: Sevinj Gahramanova
Session: Poster Display
Resources:
Abstract
52P - A comparative study to assess volumetric and dosimetric profile of heart and lung in patients undergoing left sided post mastectomy radiotherapy: Continuous positive airway pressure (CPAP) versus free breathing (FB) techniques
Presenter: Pritanjali Singh
Session: Poster Display
Resources:
Abstract
29P - HUWE1 inhibition has tumor suppressive effect in triple-negative breast cancer cell lines by modulating glycolytic and immune modulatory markers
Presenter: Shruti Kahol
Session: Poster Display
Resources:
Abstract
53P - Radiotherapy utilization rate for breast cancer in Indonesia: A call for empowering cancer care
Presenter: Donald Manuain
Session: Poster Display
Resources:
Abstract
58P - Safety and pharmacokinetics (PK) of vepdegestrant in Japanese patients with estrogen receptor (ER)+/human epidermal growth factor receptor 2 (HER2)- advanced breast cancer: Results from a Japanese phase I study
Presenter: Hiroji Iwata
Session: Poster Display
Resources:
Abstract
59P - Comprehensive genomic profiling (CGP) unravels druggable targets in breast carcinoma (BC): A single institutional experience
Presenter: Gautam Balaram
Session: Poster Display
Resources:
Abstract
60P - A study of gene alterations in Asian patients with late stage and recurrent breast cancer
Presenter: Po-Sheng Yang
Session: Poster Display
Resources:
Abstract
61P - Tumor cell-released autophagosomes (TRAPs) remodel the breast tumor microenvironment by inducing the formation of inflammatory cancer-associated fibroblasts (CAFs)
Presenter: Chengdong Wu
Session: Poster Display
Resources:
Abstract
62P - Combination of chemotherapy with endocrinal therapy as upfront treatment of metastatic breast cancer in hormone receptor- positive, HER2 -negative disease: A phase II randomised clinical trial
Presenter: Mariam Saleh
Session: Poster Display
Resources:
Abstract